CD38 Monoclonal Antibody (HIT2), FITC, eBioscience™, Invitrogen™

Description

• Description: The HIT2 monoclonal antibody reacts with the human CD38 molecule, an approximately 45 kDa type II transmembrane protein
• CD38 is expressed by thymocytes, peripheral B cells including plasma cells, activated T cells, and monocytes
• CD38 is a counter-receptor for CD31 and has both cyclase and hydrolase enzymatic activity
• Applications Reported: The HIT2 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The HIT2 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (1 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells
• CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor
• Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e
• identification of myelomas), and as a marker for activated B and T cells
• CD38 participates in cell adhesion, signal transduction and calcium signaling
• Further, CD38 is expressed at high levels in the pancreas, liver, kidney, malignant lymphoma and neuroblastoma
• Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter's Syndrome.